Interpace Biosciences Inc (IDXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 38,728 | 46,926 | 40,036 | 31,838 | 33,117 |
| Cost of Goods | 14,598 | 17,001 | 14,980 | 13,607 | 14,314 |
| Gross Profit | 24,130 | 29,925 | 25,056 | 18,231 | 18,803 |
| Operating Expenses | 20,644 | 21,818 | 22,080 | 22,455 | 25,453 |
| Operating Income | 4,084 | 8,108 | 3,956 | -3,617 | -6,336 |
| Interest Expense | 0 | 34 | 112 | 158 | 496 |
| Other Income | -310 | -1,124 | -1,563 | -2,061 | -910 |
| Pre-tax Income | 3,774 | 6,950 | 2,281 | -5,836 | -7,742 |
| Income Tax | -21,210 | 4 | 17 | 29 | -705 |
| Net Income Continuous | 24,984 | 6,946 | 2,264 | -5,865 | -7,037 |
| Net Income Discontinuous | -409 | -244 | -310 | -16,093 | -7,906 |
| Net Income | $24,575 | $6,702 | $1,954 | $-21,958 | $-14,943 |
| EPS Basic Total Ops | 5.55 | 1.42 | 0.45 | -5.18 | -3.61 |
| EPS Basic Continuous Ops | 5.65 | 1.48 | 0.52 | -1.38 | -1.70 |
| EPS Basic Discontinuous Ops | -0.09 | -0.06 | -0.07 | -3.80 | -1.91 |
| EPS Diluted Total Ops | 0.89 | 0.40 | 0.45 | -5.18 | -3.61 |
| EPS Diluted Continuous Ops | 0.90 | 0.41 | 0.52 | -1.38 | -1.70 |
| EPS Diluted Discontinuous Ops | -0.01 | -0.02 | -0.07 | -3.80 | -1.91 |
| EPS Diluted Before Non-Recurring Items | 0.90 | 0.41 | 0.25 | -1.38 | N/A |
| EBITDA(a) | $4,963 | $8,856 | $5,599 | $8,378 | $-840 |